All Stories

  1. Clinical and Serological Biomarkers of Treatment’s Response in Multiple Sclerosis Patients Treated Continuously with Interferonβ-1b for More than a Decade

    Article • CNS & Neurological Disorders - Drug Targets, November 2018, Bentham Science Publishers

    Dr Smaranda Maria Maier, Zoltán Bajko , Adina Hutanu, Rodica Balasa

  2. The Matrix Metalloproteinases Panel in Multiple Sclerosis Patients Treated with Natalizumab: A Possible Answer to Natalizumab Non- Responders

    Article • CNS & Neurological Disorders - Drug Targets, August 2018, Bentham Science Publishers

    Adina Hutanu, Dr Smaranda Maria Maier, Bianca Emilia Ciurba, Septimiu Voidazan

  3. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action

    Article • CNS & Neurological Disorders - Drug Targets, January 2018, Bentham Science Publishers

    Dr Smaranda Maria Maier, Adina Hutanu, Rodica Balasa, Mihaela Adriana Simu, Zoltán Bajko